The closing price of Biora Therapeutics Inc (NASDAQ: BIOR) was $1.42 for the day, down -7.79% from the previous closing price of $1.54. In other words, the price has decreased by -$0.1200 from its previous closing price. On the day, 1947232 shares were traded.
Ratios:
Our analysis of BIOR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.28 and its Current Ratio is at 0.28.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOR now has a Market Capitalization of 38.39M and an Enterprise Value of 108.21M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1931.91. Its current Enterprise Value per Revenue stands at 6.01k whereas that against EBITDA is -0.98.
Stock Price History:
The Beta on a monthly basis for BIOR is 1.18, which has changed by -51.11% over the last 52 weeks, in comparison to a change of 27.55% over the same period for the S&P500. Over the past 52 weeks, BIOR has reached a high of $6.70, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is 1.0809, while the 200-Day Moving Average is calculated to be 2.4615.
Shares Statistics:
BIOR traded an average of 664.73K shares per day over the past three months and 450.97k shares per day over the past ten days. A total of 27.21M shares are outstanding, with a floating share count of 24.50M. Insiders hold about 9.96% of the company’s shares, while institutions hold 47.69% stake in the company. Shares short for BIOR as of Feb 15, 2024 were 714.57k with a Short Ratio of 1.07, compared to 592.33k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.63% and a Short% of Float of 2.79%.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.59 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.74, while EPS last year was -$0.75. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$7.78 and -$8.39 for the fiscal current year, implying an average EPS of -$8.08. EPS for the following year is -$2.05, with 2 analysts recommending between -$1 and -$3.11.
